Study to assess efficacy and safety of Yasmin in an extended cycle regimen
Please see attached Study Results Summary below.
No Inclusion Criteria Available
No Exclusion Criteria Available
Prospective, multi-center, open, uncontrolled study to investigate the efficacy, safety and acceptance of SH T 470 FA (Yasmin® [30μg ethinylestradiol and 3mg drospirenone]) in an extended cycle regimen of up to 36 weeks for oral contraception in 200 female volunteers